<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459926</url>
  </required_header>
  <id_info>
    <org_study_id>0084</org_study_id>
    <nct_id>NCT01459926</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and&#xD;
      Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the weekly average CSBMs over Weeks 2 to 5 of treatment</measure>
    <time_frame>Between weeks 2 and 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the weekly SBM frequency in the last week of treatment</measure>
    <time_frame>baseline and 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Opioid Induced Constipation</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>once daily</description>
    <arm_group_label>Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of constipation with onset after initiation of opioid therapy&#xD;
&#xD;
          -  Self-reported OIC of approximately 3 spontaneous bowel movements (SBMs) per week or&#xD;
             less for each week over at least the previous two week period&#xD;
&#xD;
          -  Have used chronic opioids with a total daily dose â‰¥30 mg of morphine equivalent units&#xD;
             (MEU, Appendix 7) for the 12 weeks preceding the Screening Visit. Subjects should have&#xD;
             used a stable daily regimen of opioids for at least the 2 weeks preceding the&#xD;
             Screening Visit&#xD;
&#xD;
          -  Willing to stop all laxatives and other bowel regimens with the exception of&#xD;
             bisacodyl/enema treatment allowed per protocol throughout the OIC confirmation,&#xD;
             treatment, and follow-up periods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have participated in a clinical trial of an investigational drug or medical device&#xD;
             within 30 days prior to Screening&#xD;
&#xD;
          -  Have any condition that may affect drug absorption, (e.g., previous GI surgery)&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, could confound or&#xD;
             interfere with evaluation of safety or tolerability of the investigational drug, or&#xD;
             prevent compliance with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>G and L Research, LLC</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <zip>36535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <disposition_first_submitted>June 5, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 5, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 13, 2013</disposition_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid induced constipation</keyword>
  <keyword>OIC</keyword>
  <keyword>Constipation</keyword>
  <keyword>Opioid side effects</keyword>
  <keyword>Morphine induced constipation</keyword>
  <keyword>Opioid therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Opioid-Induced Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

